• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

Alzheimer's disease

Athira Pharma’s stock falls 39% after placing its CEO on leave

June 18, 2021 By Brian Buntz

The Bothell, Wash.–based clinical-stage biopharma Athira Pharma (NSDQ:ATHA) is in a tailspin after the company’s board put Leen Kawas, the firm’s CEO, on temporary leave. The company’s stock closed the day at an all-time low of $11.15. The stock was valued as high as $34.25 on Dec. 31, 2020. Washington State University has launched an […]

Filed Under: Business/Financial News, Featured, Neurological, Pharmaceutical Tagged With: Alzheimer's, Alzheimer's disease, Athira Pharma

Unraveling aducanumab’s impact remains a challenge

June 16, 2021 By Brian Buntz

The FDA’s conditional approval of Biogen’s (NSDQ:BIIB) and Eisai’s (OTCMKTS:ESALY) Alzheimer’s drug aducanumab (Aduhelm) may have been controversial, but the decision will likely have a significant financial impact. There are 6 million people with Alzheimer’s in the U.S. alone, according to Alzheimer’s Association estimates. Approximately half of those patients have mild symptoms, which is the group most likely […]

Filed Under: Featured, Food & Drug Administration (FDA), Imaging, Neurological, Pharmaceutical, Regulatory/Compliance Tagged With: Alzheimer's disease, Biogen, Cardinal Health, Eisai

8 Alzheimer’s disease breakthroughs you need to know

June 29, 2018 By Danielle Kirsh

  Alzheimer’s is a form of dementia that can cause problems with memory, thinking and behavior, according to the Alzheimer’s Association. It is the most common form of dementia that gets worse over time. Nearly 6 million Americans presently live with Alzheimer’s— and there’s no cure for it. The disease is caused by protein buildups […]

Filed Under: Implants, Neurological, Neuromodulation/Neurostimulation, Research & Development Tagged With: Alzheimer's disease, Augusta University, cognitotherapeutics, DARPA, Indiana University, MedTech, neurodegenerative diseases, NeuroVision, Northwestern University, University of Illinois, Yale Medicine

DARPA is developing a human memory prosthesis: Here’s how

April 4, 2018 By Danielle Kirsh

The Defense Advanced Research Projects Agency (DARPA) has successfully created what it is calling a human memory prosthesis, a system with electrodes implanted in the brain that restores memory function using a person’s own neural codes. DARPA has been working on restoring normal memory function in military personnel since 2013 in a program known as […]

Filed Under: Neurological, Prosthetics, Regenerative Medicine, Research & Development Tagged With: Alzheimer's disease, DARPA, memory loss, prosthesis, University of Southern California, Wake Forest Baptist Medical Center

How WiFi could monitor sleep disorders

August 8, 2017 By Danielle Kirsh

Monitoring sleep disorders could be as easy as measuring the radio waves around a patient through WiFi, according to new research from Massachusetts Institute of Technology and Massachusetts General Hospital. Some people suffer a lot during the night when they´re not able to sleep, that´s why it is very important to go through every detail […]

Filed Under: Diagnostics, Research & Development Tagged With: Alzheimer's disease, Massachusetts General Hospital, Massachusetts Institute of Technology, MedTech, mit, Parkinson's disease, sleep disorders

Study: Alzheimer’s ‘seeds’ may spread in medical procedure

September 9, 2015 By MassDevice

(Reuters) — British scientists have found evidence that the biological seeds of Alzheimer’s disease could be passed on through medical procedures – though specialists said the risk of transmission was largely theoretical. Research published today found evidence that suggested 1 of the hallmark proteins of Alzheimer’s – that could go on to develop into the brain disease – spread to […]

Filed Under: Clinical Trials, Neurological Tagged With: Alzheimer's disease

Cervel Neurotech raises $11M for device-based depression therapy

June 9, 2014 By Arezu Sarvestani Leave a Comment

Cervel Neurotech raises $11M for device-based depression therapy

California-based medical device maker Cervel Neurotech is nearing the close of an $11.9 million funding round, having raised $11.1 million since April 2013 in support of its technology-based therapies for neurological and psychiatric disorders.

Filed Under: Funding Roundup, Neurological, Neuromodulation/Neurostimulation, News Well Tagged With: Alzheimer's disease, Cervel Neurotech, Psychiatry

GE Healthcare’s new Vizamyl Alzheimer’s disease detector comes to the U.S.

April 29, 2014 By Arezu Sarvestani Leave a Comment

GE Healthcare launches Vizamyl Alzheimer's disease detector

GE Healthcare’s (NYSE:GE) newly FDA-approved Vizamyl imaging agent is about to make its initial appearance in 7 U.S. markets, where doctors can use it to help diagnose patients with Alzheimer’s disease and dementia.

Filed Under: Neurological, News Well Tagged With: Alzheimer's disease, GE Healthcare

GE Healthcare lands FDA approval for new Alzheimer’s disease imaging agent

October 28, 2013 By Arezu Sarvestani

GE Healthcare lands FDA approval for new Alzheimer's disease imaging agent

Filed Under: Food & Drug Administration (FDA), Imaging, Neurological, News Well, Pre-Market Approval (PMA), Regulatory/Compliance Tagged With: Alzheimer's disease, GE Healthcare

Alzheimer’s disease: FDA expands deep-brain stimulation trial

July 10, 2013 By Arezu Sarvestani Leave a Comment

FunctionalNeuromodulation Logo

Toronto-based Functional Neuromodulation won FDA approval to expand the U.S. arm of its Alzheimer’s study from 20 to 30 patients who will receive the company’s deep brain stimulation implant.

The device maker is already halfway through initial enrollment for its ADvance trial, which was slated to enroll 20 U.S. and 20 Canadian patients with mild Alzheimer’s disease, provide them with DBS systems and compare the effects of the systems turned on versus systems turned off.

Filed Under: Food & Drug Administration (FDA), Neuromodulation/Neurostimulation, News Well Tagged With: Alzheimer's disease, Clinical Trials, Deep-brain stimulation, Functional Neuromodulation

Doctors in NY nearly harvest organs from living woman | MassDevice.com On Call

July 9, 2013 By Sony Salzman Leave a Comment

MassDevice On Call

MASSDEVICE ON CALL — A woman proclaimed dead following her drug overdose opened her eyes on the operating table as her body was being prepped for donor organ removal. The gruesome hospital mishap, which took place in 2009, was revealed when the Syracuse Post-Standard pushed for documents under the Freedom of Information Act.

The woman, Colleen Burns, committed suicide 16 months later. Her family has not sued the hospital, but New York state health officials issued a $6,000 fine and the Center for Medicare & Medicaid services chided the hospital for a lack of internal investigation.

Filed Under: Healthcare Reform, News Well Tagged With: Alzheimer's disease, Eli Lilly & Co., On Call

  • Page 1
  • Page 2
  • Page 3
  • Go to Next Page »

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy